NOXXON announces presentation of NOX-A12 Phase 1/2 data in glioblastoma at the 2022 ASCO Annual Meeting and invitation to a dedicated KOL event

• Full top-line results from dose escalation of NOX-A12 Phase 1/2 GLORIA trial in brain cancer to be presented at ASCO 2022 on June 5, 2022
• Key Opinion Leader (KOL) webinar with lead investigator of the GLORIA trial Dr. Frank A. Giordano to discuss study data in more detail on June 10, 2022

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces publication of the abstract of its poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting which will take place in Chicago, Illinois, US, from June 3 to June 7, 2022.

The poster presentation entitled “Radiotherapy and olaptesed pegol (NOX-A12) in partially resected or biopsy-only MGMT-unmethylated glioblastoma: Interim data from the German multicenter phase 1/2 GLORIA trial” will be presented by Dr. Frank A. Giordano and will exhibit the top-line results of the Phase 1/2 GLORIA trial in brain cancer (glioblastoma).

Specifically, the abstract highlights that:
• 40% of patients achieved partial response (PR defined as tumor size reduction over 50%), a considerable increase over the 22% previously disclosed and as reported in March 2022
• In 3 out of 10 patients, one or more non-target lesions (smaller secondary lesions) completely disappeared
• The combination of radiotherapy and NOX-A12 was safe and well-tolerated, with no dose limiting toxicities and no treatment-related deaths. Only 4% of the adverse events of Grade 2 or more were deemed solely NOX-A12-related.

The abstract can be accessed here and more information about the GLORIA study (NCT04121455) can be found at ClinicalTrials.gov.

Details of the poster presentation are as follows:
Title: Radiotherapy and olaptesed pegol (NOX-A12) in partially resected or biopsy-only MGMT-unmethylated glioblastoma: Interim data from the German multicenter phase 1/2 GLORIA trial (poster #2050)
Abstract: download
Session Title: Central Nervous System Tumors
Session Date: Sunday, June 5, 2022
Presentation Time: 08:00-11:00 a.m. CDT (03:00-06:00 p.m. CEST)
Presenter: Dr. Frank Giordano, Director and Chairman of the Department of Radiation Oncology at the University Hospital Bonn, Germany
Registration: To register to the event, please click here.

The NOXXON team will attend the conference in person. A copy of the poster presentation including a video describing the poster will be made available on the NOXXON website at the time of Dr. Giordano’s presentation.

Following the ASCO 2022 conference, NOXXON will host a Key Opinion Leader (KOL) webinar with Dr. Giordano who will take the audience through the ASCO poster presentation and discuss the results of the GLORIA Phase 1/2 trial in more detail.

Details of the Key Opinion Leader webinar are as follows:
Title: KOL Webinar on GLORIA Top-Line Results of NOX-A12 & Radiotherapy Combination in First-Line Glioblastoma Presented at ASCO 2022
Presenter: Dr. Frank A. Giordano, Director and Chair of the Department of Radiation Oncology, University
Hospital Bonn, Germany
Webinar time and date: June 10, 2022, at 02:00 p.m. CEST (08:00 a.m. EDT)
Registration: To register for the event, please click here

About the GLORIA Study

GLORIA (NCT04121455) is NOXXON’s dose-escalation, phase 1/2 study of NOX-A12 in combination with irradiation in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 three additional arms combining NOX-A12 with: A. radiotherapy in patients with complete tumor resection; B. radiotherapy and bevacizumab in patients with incomplete tumor resection; and C. radiotherapy and pembrolizumab in patients with incomplete tumor resection.

About the OPTIMUS Study

OPTIMUS (NCT04901741) is NOXXON’s open-label two-arm phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

Disclaimer

Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.